CCL2 and breast carcinoma: Although anti-CCL2 mAb significantly reduced TAMs in the TME during treatment, withdrawal of the antibody leads to accelerated metastasis of breast cancer cells due to the rapid rebound of monocyte recruitment [23, 28, 30, 38, 155, 158, 161].